

University of Oxford
Nuffield Population Health Group
Clinical Trials and Epidemiological Studies Unit
Richard Doll Building, Roosevelt Drive
Oxford OX3 7LF, England

Louisa Gnatiuc, MSc
Senior Epidemiologist
louisa.gnatiuc@ndph.ox.ac.uk

Dear Sir/ Madam

Re: Application for a Nucleus Member within the ERS Council on Hypertension

I am an epidemiologist in the Nuffield Department of Health at the University of Oxford, currently working on adiposity and hypertension and cardio-vascular risks for premature mortality in prospective cohorts of 150,000 and 1 million people ([Oxford NDPH Gnatiuc](#)), and I am to start a doctorate on adiposity and vascular risks. My interests are avoiding premature mortality, metabolomic signatures for vascular risks and guidelines. My interest for joining the council is in the use of evidence for curbing the hypertension epidemic and the interplay between aetiology, treatments and large scale epidemiology.

Yours sincerely

Louisa Gnatiuc

Louisa Gnatiuc

Education

- 2016- Doctoral Candidate, Population Studies, University of Oxford
2005-2006 MSc in Public Health, London School of Hygiene and Tropical Medicine, London University

Employment and Honorary

- July 2014 Senior Epidemiologist, University of Oxford, Nuffield Population Health, CTSU
Honorary Research Officer, Imperial College London
- 2009-2014 Coordinator for the Burden of Obstructive Lung Disease, Imperial College London
Honorary Research Assistant, Imperial College NHS Trust, London
- 2008-2009 Study Manager, UK Register of HIV Seroconverters, Medical Research Council
Honorary Research Assistant, University College London
- 2007-2008 TB Research Nurse, Imperial College NHS Trust, St. Mary's Hospital London
- 2006-2007 Research Integration Co-ordinator for the GA2LEN studies, Imperial College London
- 1992-2005 Senior Registered Nurse, Acute Medicine Ward, Onesti Hospital Romania
- 2000-2002 Head of a Public Health Projects in Senegal and Angola , ADRA

Consultancy

- UK Department of Health – Group Advisory expert opinion on National Programs for COPD
Bayer Schering Pharma Germany – Study feasibility on respiratory complications for new therapies
GlaxoSmithKline UK –European study on cardio-vascular comorbidities

Boards and Committees

- Burden of Obstructive Lung Disease Advisory Board and Steering Committee (2009-2015)
GA2LEN Research Network Advisory Board (2006-2007)

Selected Publications

Gnatiuc L, JA Diaz, W Herrington et al, Adiposity and blood pressure: a cross-sectional analysis of 150 000 adults recruited into the Mexico City Prospective Study. *(In preparation for IJE)*

Gnatiuc L, JA Diaz, W Herrington et al, Health insurance burden of hypertension treatment and control and excess mortality. Evidence from a 12-years prospective study in adults from the Mexico City Prospective Study. *(In preparation for JAMA)*

Gnatiuc L, Halsey J, Emberson J, Lewington S, for the APCSC and the PSC Collaboration. Diabetes, cause-specific mortality and survival. Evidence from 77,000 deaths in 1million adults from 68 cohorts in 19 countries. *(In preparation for Lancet Diabetes)*

JA Diaz, W Herrington, M López-Cervantes, **L Gnatiuc**, et al, Substantial increases in the leading causes of death in those with diabetes: 12-year prospective study of 150,000 Mexican adults. *NEJM (under review)*

A. Amaral, J Patel, **L Gnatiuc** et al, Association of pulse wave velocity with total lung capacity: A cross-sectional analysis of the BOLD London study. *Respiratory Medicine* 2015, Dec;109(12):1569-75

Gnatiuc L, Buist S, Kato B, et al. The gap in use of bronchodilators, inhaled corticosteroids and influenza vaccine among 23 sites in 20 countries. Results from BOLD study. *IUATLD Journal*, 2015 Jan;19(1):21-30

Gnatiuc L, Caramori G. COPD in non-smokers: the biomass hypothesis. To be or not to be? *Eur Respir J*. 2014 Jul;44(1):8-10.

Grønseth R, Vollmer WM, Hardie JA, et al. Predictors of dyspnea prevalence: Results from the BOLD study" *Eur Respir J*. 2014 Jun;43(6):1610-20.